Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Podcast

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

This week, CancerNetwork® spoke with Muhammad Niazi, MD, resident in internal medicine at Staten Island University Hospital, and Alexander Bershadskiy, MD, attending physician at Staten Island University Hospital, about a meta-analysis published in ONCOLOGY® titled, “Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.”

The final analysis evaluated 3 randomized clinical trials. A fixed model showed a statistically significant improvement in overall survival for patients with metastatic castration-resistant prostate cancer treated with PARP inhibitors.

The authors provided a detailed background on PARP inhibitors and further detailed the results of this research, focusing on increased survival with PARP inhibitor treatment for this patient population.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Related Content
Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.

Data Show Short-Course Radiotherapy Increase in Prostate Cancer

November 30th 2023
Article

Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Adapting to a Robotic Workstation for Image-Guided Liver Cancer Surgery

December 4th 2023
Podcast

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Docetaxel plus standard of care may be beneficial among patients with prostate cancer and low prostate-specific antigen levels who do not have any highly effective treatment options, says Anthony D’ Amico, MD, PhD.

Docetaxel/SOC Significantly Reduces Mortality in Low PSA Prostate Cancer

November 7th 2023
Article

Docetaxel plus standard of care may be beneficial among patients with prostate cancer and low prostate-specific antigen levels who do not have any highly effective treatment options, says Anthony D’ Amico, MD, PhD.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

With the announcement that the supply of 177Lu vipivotide tetraxetan is now unconstrained, the targeted radioligand will be available in over 200 centers for patients with prostate cancer.

FDA Classifies 177Lu Vipivotide Tetraxetan Drug Shortage as Resolved

October 31st 2023
Article

With the announcement that the supply of 177Lu vipivotidete traxetanis now unconstrained, the targeted radioligand will be available in over 200 centers for patients with prostate cancer. 

Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic castration-resistant prostate cancer in the phase 1/2 study ONCT-534-101.

ONCT-534 Earns FDA Fast Track Designation in R/R Metastatic CRPC

October 27th 2023
Article

Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic castration-resistant prostate cancer in the phase 1/2 study ONCT-534-101.